Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 16/20 | 0.73 |
| ▸ | HTR1A | P08908 | 3/20 | 0.48 |
| ▸ | HTR1D | P28221 | 2/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3143198 | 0.85 | HTR6 (1.00) | HTR6HTR1AHTR1DMPO | |
| Hydrochloric Acid SCHEMBL3142854 | 0.84 | HTR6 (0.98) | HTR6HTR1AHTR1DMPO | |
| SCHEMBL3323841 | 0.83 | HTR6 (0.74) | HTR6HTR1AHTR1DMPOHTR1B | |
| SCHEMBL3156930 | 0.81 | HTR6 (1.00) | HTR6HTR1AHTR1DHTR1B | |
| SCHEMBL3144603 | 0.80 | HTR6 (1.00) | HTR6HTR1AHTR1DMPOHTR1B | |
| SCHEMBL3147480 | 0.79 | HTR6 (1.00) | HTR6HTR1AHTR1DHTR1B | |
| SCHEMBL3143201 | 0.78 | HTR6 (0.89) | HTR6HTR1AHTR1DHTR1B | |
| SCHEMBL5659589 | 0.78 | HTR6 (0.53) | HTR6HTR1AHTR1DMPOHTR1B | |
| SCHEMBL4970689 | 0.77 | HTR6 (0.83) | HTR6HTR1AHTR1DMPOHTR1B | |
| SCHEMBL3156829 | 0.77 | HTR6 (1.00) | HTR6HTR1AHTR1DMPOHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176200-B2 | Derivatives of sulphonamides, their preparation and use as medicaments | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2007-02-13 | — | — | US | disclosed |
| US-20050032791-A1 | Such as N-[3-(2-diethylaminoethyl)-1H-indol-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulphonamide for treating anxiety, depression, cognitive memory disorders and senile dementia, psychosis, infant hyperkinesia (ADHD, attention deficit/hyperactivity disorder) | MERC-VIDAL RAMON (ES) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032791-A1 | Such as N-[3-(2-diethylaminoethyl)-1H-indol-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulphonamide for treating anxiety, depression, cognitive memory disorders and senile dementia, psychosis, infant hyperkinesia (ADHD, attention deficit/hyperactivity disorder) | CHAT, SLC6A3, PSEN2 | HTR6 10/4885HTR1A 26/4885HTR1D 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.